Boundless Bio made a play to become the seventh US biotech to seek a public listing in 2024, ending a brief hiatus in IPO activity after a busy start to the year.
Cambridge, Massachusetts-based FogPharma has closed another impressive fundraising round, adding $178 million to the pot as it ushers its polypeptide-based drug candidates towards the clini